Tuesday, October 15, 2019
Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes
  SocialTwist Tell-a-Friend  

BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- Novo Nordisk announced today the results from two Ozempic (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed:

  • Ozempic was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and body weight in people with type 2 diabetes uncontrolled on metformin.1
  • Ozempic was superior to Victoza (liraglutide 1.2 mg) in reducing HbA1c and body weight in people with type 2 diabetes.2

These data were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, and simultaneously published in The Lancet Diabetes & Endocrinology (SUSTAIN 8) and Diabetes and Metabolism (SUSTAIN 10).1,2

"We are proud of the superior clinical profile of once-weekly Ozempic , as demonstrated through all the SUSTAIN clinical trials, and encouraged by these new data which further reinforce the value of Ozempic for people with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

These trials form part of the extensive SUSTAIN programme, a global clinical development programme that comprises more than 10 Phase 3 trials involving more than 10,065 adults with type 2 diabetes. To date, outcomes of SUSTAIN 1-7 and 9 have been published demonstrating Ozempic is a best-in-class, efficacious and well-tolerated treatment option for people with type 2 diabetes.


At 52 weeks, Ozempic demonstrated a superior reduction in mean HbA1c of 1.5% compared to canagliflozin at 1.0%, from a baseline of 8.3%. In addition, 66.1% of people treated with Ozempic achieved HbA1c treatment target <7% vs 45.1% of those treated with canagliflozin. People treated with Ozempic also demonstrated superior reductions in body weight compared with canagliflozin with 5.3 kg vs 4.2 kg, respectively, from a mean baseline of 90.2 kg. Significantly more people treated with Ozempic achieved reduction in body weight of ≥10% vs canagliflozin (22.3% vs 8.9%, respectively).

"To date, head-to-head trials of GLP-1 receptor agonists and SGLT-2 inhibitors have been limited," said Dr Ildiko Lingvay, University of Texas Southwestern Medical Centre, Dallas, and lead study investigator. "These data seen in the SUSTAIN 8 trial support Ozempic as an efficacious treatment option for reducing blood sugar and body weight for people with type 2 diabetes after metformin."


At 30 weeks, Ozempic demonstrated a superior reduction in mean HbA1c compared to Victoza (1.7% vs 1.0% respectively), from a mean baseline of 8.2%. In addition, 80% of people treated with Ozempic achieved HbA1c treatment target of <7% vs 46% of those treated with Victoza . People treated with Ozempic also demonstrated superior reductions in body weight compared with Victoza with 5.8 kg vs 1.9 kg, respectively, from a mean baseline of 96.9 kg. Significantly more people treated with Ozempic achieved reduction in body weight of ≥10% than those treated with Victoza (19% vs 4%, respectively).

"Intensifying treatment with Ozempic showed significant benefits over Victoza in terms of blood sugar control and reduction in body weight, providing an alternative treatment option for those uncontrolled on current treatment," said Dr Matthew Capehorn, Rotherham Institute for Obesity, UK, and lead study investigator.

The tolerability of once-weekly Ozempic was generally similar to that of Victoza and canagliflozin, except for higher rates of gastrointestinal adverse events (AEs) with Ozempic vs Victoza and more frequent infections and infestations with canagliflozin vs Ozempic . The safety profile of Ozempic 1.0 mg in both trials was consistent with the overall SUSTAIN clinical trial programme.

About Ozempic

Once-weekly Ozempic (semaglutide) is an analogue of human glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.3,4 Ozempic was first approved by the US FDA in 2017 and is now launched in 25 countries.


SUSTAIN 8 is a 52-week double-blinded Phase 3 trial investigating the efficacy and safety of once-weekly Ozempic (semaglutide 1.0 mg) vs canagliflozin 300 mg as add-on to metformin in people with type 2 diabetes. The primary endpoint was change in HbA1c from baseline to Week 52, and key secondary endpoints include change in body weight at Week 52 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 52.1

About SUSTAIN 10

SUSTAIN 10 is a 30-week open-label Phase 3b trial investigating the safety and efficacy of Ozempic 1.0 mg once-weekly vs Victoza 1.2 mg once-daily, as add-on to 1–3 oral antidiabetics (OADs) in 577 adults with type 2 diabetes in Europe. The primary endpoint was change in HbA1c at Week 30, and key secondary endpoints include change in body weight at Week 30 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 30.2

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.


  1. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. Published Online 17 September 2019. http://dx.doi.org/10.1016/PII
  2. Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab (2019). https://doi.org/10.1016/j.diabet.2019.101117
  3. EMA. Ozempic Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf. Last accessed: September 2019.
  4. FDA. Ozempic US Prescribing Information. December 2017. Available at: http://www.novo-pi.com/ozempic.pdf Last accessed: September 2019.

Further information


Mette Kruse Danielsen

+45 3079 3883


Ken Inchausti (US)

+1 609 240 9429



Peter Hugreffe Ankersen

+45 3075 9085


Kristoffer Due Berg (US)

+1 609 235 2989


Valdemar Borum Svarrer

+45 3079 0301


Ann Søndermølle Rendbæk

+45 3075 2253


More News by PR Newswire India

Shanghai International Money Fair - one of China's largest financial fairs will be held in December

Europe's Most Trusted Crypto And Precious Metal Companies Partner To Create Gold Token Secured By Bitcoin Network

RGE Commits US$200 Million to Next-Generation Textile Fibre Innovation and Technology

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

INSIDE INFORMATION: BW LPG Contemplated Sale of Shares

School House Crafts Multi-Sensory Journey of Discovery and Re-collection for La Mer Campaign Exhibition

Vevue Partners with CBX Exchange for Initial Auction Offering

Frost & Sullivan Recognizes Pepco Holdings and Carlsbad Municipal Water District with Excellence in Resourcefulness Awards at Itron Utility Week

His Holiness The Dalai Lama Awarded Honorary Doctorate by Chitkara University

Surplus Keslow Cinematography Gear Up For Auction

Libyan Investment Authority Loses Claim in the UK Court of Appeal - London

Artificial Intelligence for Risk Management Process by MovingNow

Maruti Suzuki Arena Devils Circuit Season 2019-20 Draws Over 6K Runners in Hyderabad

Quectel Achieves Industry's First 5G Data Call over 5G mmWave Module

Artprice by Artmarket: The Gagosian's Grand Projects for the Late Simon Hantaï (1922-2008)

Ryan International Group of Schools Receive India's Most Respected Brand Award 2019

JD Institute Of Fashion Technology, South Announced its New Domain

VeChain Is Leading Co-sponsor of GDST Seafood Trackathons

The World's Largest Automakers, Along with MOBI, Announce a Joint Proof of Concept for the First Vehicle Identity on Blockchain

Indiannica Learning Announces the Launch of Indiannica Quiz League

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

Telangana: Three members appointed to Te...
SC seeks status report on stubble burnin...
US Navy submarine support ship arrives i...
UP govt suspends Maharajganj DM, five ot...
Delhi cabinet nod for new skill, entrepr...
Ex-chief engineer arrested in Tripura PW...
 Top Stories
Maha polls: Rahul to hold two publi... 
Miranda Lambert posts adorable birt... 
Heavy rain predicted in Kerala, Kar... 
Devastating fire breaks out at plas... 
Zoe Kravitz roped in to play Catwom... 
Turkish troops advance towards Manb... 
CA to match prize money for women's... 
Phil Simmons appointed the head coa...